ASX / Media Release
27 September 2021

Invex and Peptron Sign Exclusive Collaboration & Manufacturing Agreement for Presendin™ in IIH

Invex Therapeutics Ltd (**Invex**, **ASX:IXC,** or **the Company**), a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ for neurological conditions relating to raised intracranial pressure, is today pleased to announce the signing of a long term Collaboration and Manufacturing Agreement with Peptron, Inc. (KOSDAQ: 087010), a biopharmaceutical company developing sustained-release peptide-based medicines with high technological barriers to treat chronic diseases, based in Daejeon, Korea.

Under the terms of the agreement, Peptron will provide Invex with access to its intellectual property, including an extensive preclinical and clinical data package, and Presendin™ for all of its clinical trials in idiopathic intracranial hypertension (IIH) as well as for commercial use, once Presendin™ is approved. The agreement between the companies is exclusive, applies globally and provides a defined price per dose for the supply of Presendin™ for clinical studies and for the first ten years following the first commercial sale. In addition, Invex has granted Peptron an exclusive license to commercialise it for IIH in Korea.

Presendin™ is a once weekly sub-cutaneous formulation of Exenatide that reduces injection frequency, provides greater convenience for patients, and typically leads to greater patient compliance. Presendin™ will be manufactured and supplied globally to Invex from Peptron's manufacturing facility in Osong, Korea, which can produce over 48,000 vials of Presendin™ per month. This collaboration will ultimately lead to an expansion of Peptron's GMP manufacturing capacity in Korea to meet expected commercial demand.

"We are pleased to be partnering with Invex in their pursuit of Presendin™, which is ideally suited to meet the clinical and commercial supply requirements at this important stage of their development. Moreover, our state-of-the-art GMP manufacturing facility is ideal for Presendin™ manufacturing with the aseptic process for the Dry Powder Injectable other than Lyophilized or Liquid Injectable." said Dr. Ho-il Choi, CEO of Peptron. "As a global leader in the development and manufacture of sustained-release formulations (SmartDepot technology), we continue to develop this novel formulation as a treatment for neurological disorders globally, including Parkinson's disease."

Dr Jason Loveridge, Chairman of Invex commented, "This collaboration is a very significant step forward for Invex. Peptron has years of experience in both the manufacture and clinical development of Exenatide and this collaboration significantly de-risks Invex's development of Presendin™ in IIH by providing access to both drug product as well as to Peptron's critical and

extensive data package and their manufacturing and technical expertise. As a result, Invex will no longer need to undertake additional animal tolerability and human pharmacokinetic (PK) studies for Presendin™, which reduces Invex's development costs and risk and significantly expedites our planned Phase III registration study in IIH."

The financial impact of the agreement on Invex is not currently assessable, as the final design including patient numbers for the planned Phase III trial, which is expected to commence in 1H CY2022 is currently under development.

- ENDS -

This release dated 27 September 2021 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.

For more information, please contact:

Company/Investors
Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media
Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter **@InvexThera_ASX**

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.

About Idiopathic Intracranial Hypertension (IIH)

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.

About Exenatide

Exenatide is a small peptide and a synthetic version of the GLP-1 agonist exendin-4, which received approval in the US and Europe for the treatment of type 2 diabetes in 2005 and 2006 respectively. Professor Alexandra Sinclair's research showed that GLP-1 receptors are expressed in the choroid plexus in the brain and that Exenatide can bind to these receptors and reduce secretion of cerebrospinal fluid. Current Exenatide dosage forms are not optimised for IIH.

About Peptron Inc.

Since its foundation in 1997, Peptron Inc. has developed the fundamental technologies for creating sustained-release formulations to develop patient-friendly, peptide-based medicines with a high technological barriers and excellent product competitiveness for the treatment of life-threatening and chronic diseases. Peptron operates a GMP manufacturing facility for dry-powder injectable in South Korea. For more information, please visit www.peptron.com.